〔Abstract〕 Objective To analyze the effect of adjuvant treatment of two chemotherapy regimens on breast infiltrating ductal carcinoma. Methods A total of 30 patients with invasive ductal carcinoma of breast admitted to Qingyuan Maternal and Child Health Care Hospital from July 2018 to June 2020 were selected and divided into control group and observation group with 15 cases in each group by random color ball method. All patients were female. The control group was treated with epirubicin plus cyclophosphamide combined with docetaxel, while the observation group was treated with doxirubicin liposome plus cyclophosphamide combined with paclitaxel liposome, and the clinical treatment effects and adverse reactions of the two groups were compared. Results The clinical treatment effect was similar between the two groups, and the observation group was significantly better than the control group in terms of adverse reactions, with statistical significance (P < 0.05). Conclusion The therapeutic regimen of doxirubicin liposome plus cyclophosphamide combined with paclitaxel liposome will not only guarantee the therapeutic effect but also reduce the incidence rate of adverse reactions in the chemotherapy process for patients with breast infiltrating ductal carcinoma. Moreover, this method has better cost and effect.